Clinical Trials

Colorado Springs Neurological Associates is one of the largest and longest-standing neuroscience medical practices in southern Colorado.  Our aim is to deliver the highest standard of neurological care – the same level of care we would want for ourselves or our loved ones.  The Center has a dedicated clinical research institute with experienced principal investigators and a full-time research staff.  Collectively, our investigators have vast experience conducting phase II through phase IV clinical trials in a broad range of neurologic diseases affecting adults and children.


 

Multiple Sclerosis Clinical Trials

Title: Acthar Gel: A prospective observational registry of H.P Acthar Gel for the treatment of Multiple Sclerosis relapse
Sponsor: Mallinckrodt
Principle Investigator: Christen Kutz, PhD, PAC

Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy and Safety of ofatumumab administered subcutaneously versus teriflunomide administered orally in patients with relapsing forms of Multiple Sclerosis Eligibility and information
Sponsor: Novartis:
Principle Investigator: Kimberly Wagner, MD

Title: PASS
A Prospective, Multicenter, Observational Post-Authorization Safety Study to Evaluate the Long Term Safety Profile of Lemtrada Treatment in Patients with Relapsing Forms of Multiple Sclerosis
Sponsor: Genzyme
Principle Investigator: Laurence Adams, MD

Other Clinical Trials

A Multicenter, Double Blind, Placebo Controlled Study

Pennant Study:  A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral  Sclerosis   PI, Brinley

Enroll HD:  A Prospective Registry Study in a Global Huntington's Disease Cohort A CHDI Foundation Project  PI, Kutz

Elevate:  Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in People with Multiple Sclerosis (elevateMS)

Principle Investigator: Christen Kutz, PhD, PAC

 

 

Epilepsy

Title: A Phase III Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy (SP0982 Study) and in the long term follow-up Study (EP0012) Eligibility and information
Sponsor: UCB
Principle Investigator: Kimberly Wagner, MD

Parkinson’s Disease

Title: Effects of droxidopa when measuring gait speed, kyphosis, and functional reach in Parkinson’s disease.
Sponsor: Lundbeck
Principle Investigator: Laurence Adams, MD

Autonomic Dysfunction

Title: “Restore” Phase 4 Clinical Study of droxidopa in Patients with Symptomatic Neurogenic Orthostatic Hypotension- pending Eligibility and information
Sponsor: Lundbeck
Principle Investigator: Laurence Adams, MD

 

Upcoming Trials

Generations 1-A randomized, double-blind, placebo-controlled, two-cohort  parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s disease


Generations 2-A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD)


FLUENT:  A 12-Month, prospective, multicenter, two-cohort, nonrandomized, open-label study in adult patients with Relapsing Multiple Sclerosis (RMS), to investigate changes in immune phenotype biomarkers after treatment with 0.5 mg fingolimod

Research Staff